Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ CellsData from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer Allogeneic Cells to Evade Detection by the Host Immune SystemDagger™ Technology, a Feature of ALLO-316 Currently Being Investigated in a Phase 1 Study for Solid Tumors, Enables Dual AlloCAR T™ Cells to Selectively Eliminate CD70 Positive, Alloreactive Host Immune Cells While Simultaneously Killing CD19-Positive Tumor Cells SOUTH SAN FRANCISCO, Calif., Nov.

斗篷™ 和匕首™ 技术显示出减少对标准淋巴细胞减少的依赖并提高AlloCAR T性能的潜力™ CellsData来自斗篷的临床前研究™ 技术强调了设计同种异体细胞以逃避宿主免疫系统匕首检测的能力™技术，目前正在实体肿瘤的第一阶段研究中研究的ALLO-316的一个特点，使双AlloCAR T™细胞选择性消除CD70阳性，同种异体反应性宿主免疫细胞，同时杀死CD19阳性肿瘤细胞南旧金山，加利福尼亚州，11月。

03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented data highlighting the Company’s next generation Cloak™ and Dagger™ technologies designed to help enhance engraftment, expansion and the persistence of AlloCAR T cell candidates, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.

032023（GLOBE NEWSWIRE）-Allogene Therapeutics，Inc。（纳斯达克股票代码：ALLO），一家开创异基因CAR T（AlloCAR T™) 癌症产品，今天提供的数据突出了该公司的下一代斗篷™ 和匕首™ 2023年11月1日至5日在加利福尼亚州圣地亚哥举行的癌症免疫治疗学会（SITC）年会上，旨在帮助增强AlloCAR T细胞候选物的植入，扩增和持久性的技术。

The development of “off-the-shelf” CAR T products that utilize cells from healthy donors has the potential to make CAR T therapies scalable and accessible to more patients. However, the effectiveness of allogeneic CAR T cells requires controlling rejection of the allogeneic CAR T cells by the patient’s immune system.

利用来自健康供体的细胞开发“现成的”CAR T产品有可能使CAR T疗法具有可扩展性并且可供更多患者使用。然而，同种异体CAR T细胞的有效性需要控制患者免疫系统对同种异体CAR T细胞的排斥反应。

Allogene’s proprietary Cloak and Dagger technologies are two novel strategies the Company is investigating to help control immune rejection and enhance expansion, persistence, and performance of AlloCAR T cells with the use of standard lymphodepletion regimens. “These promising data show that both our Cloak and Dagger technology platforms can engineer AlloCAR T cells to minimize the potential of rejection by.

Allogene专有的斗篷和匕首技术是该公司正在研究的两种新策略，旨在帮助控制免疫排斥反应，并通过使用标准的淋巴细胞清除方案来增强AlloCAR T细胞的扩增，持久性和性能。“这些有希望的数据表明，我们的斗篷和匕首技术平台都可以设计AlloCAR T细胞，以尽量减少拒绝的可能性。